Cancer
FDA expands Janssen’s Erleada label to cover metastatic castration-sensitive prostate cancer
September 19, 2019Sales and Marketing Cancer, Erleada, FDA, Janssen, pharma, prostate cancer
Janssen has announced that the FDA has expanded the label of its androgen receptor inhibitor Erleada (apalutamide) to include the …
US, Canada and Australia simultaneously fast-track Keytruda/Lenvima combo for endometrial cancer
September 18, 2019Research and Development, Sales and Marketing Australian Therapeutic Goods Administration, Cancer, FDA, Health Canada, Lenvima, keytruda, pharma
The FDA has acted under a new initiative in collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada, …
Breaking through limits in lung cancer: Introducing The Lung Ambition Alliance
September 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, Lung Ambition Alliance, lung cancer, oncology, pharma
Patrick Connor, VP and Global Franchise Head, Tumor Drivers and Resistance Mechanisms, at AstraZeneca, discusses his company’s role in the …
Read the September edition of Pharmafocus online now!
September 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, brexit, lung cancer, medicinal cannabis, pharma
The latest monthly edition of Pharmafocus, the September issue, is available to read for free online now!With a new Prime …
UK cancer survival lagging behind other nations
September 12, 2019Research and Development Cancer, british nhs
Cancer survival in the UK is falling behind other high-income nations, despite seeing an overall improvement in survival rates, according …
BMS unveils strong five-year efficacy data for Opdivo in lung cancer
September 11, 2019Research and Development Bristol-Myers Squibb, Cancer, immunotherapy, lung cancer, pharma
Bristol-Myers Squibb has unveiled pooled five-year efficacy and safety results for its blockbuster immunotherapy Opdivo (nivolumab) drawn from two Phase …
MSD’s Keytruda approved for first-line lung cancer use on NHS Scotland
September 10, 2019Manufacturing and Production, Sales and Marketing Cancer, MSD, SMC, Scotland, keytruda, lung cancer, pharma
MSD and lung cancer patients will be celebrating the news that the pharma giant’s immunotherapy Keytruda (pembrolizumab) has been accepted …
Lilly’s LOXO-292 shrinks tumours in lung cancer trial
September 9, 2019Research and Development, Sales and Marketing Cancer, Eli Lilly, lung cancer, pharma
Eli Lilly has announced its experimental cancer drug LOXO-292, acquired in January, shrank tumours in almost 70% of advanced lung …
Age affects efficacy of immunotherapy treatments in breast cancer patients
September 9, 2019Research and Development, Sales and Marketing Cancer, breast cancer, pharma
Recent clinical trial data has shown that immune checkpoints blockade (ICB) therapy, designed to unleash a patient’s immune system to …
AstraZeneca’s Imfinzi combo tops chemotherapy in treatment-naive advanced lung cancer
September 9, 2019Sales and Marketing AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
AstraZeneca has unveiled new Phase 3 data for its immunotherapy Imfinzi (durvalumab), showing that it achieved its primary endpoint when …
Roche celebrates European approval of Tecentriq combo in first-line lung cancer
September 6, 2019Medical Communications, Sales and Marketing Cancer, Europe, Roche, lung cancer, pharma, tecentriq
Roche has confirmed that its immunotherapy Tecentriq (atezolizumab) has been approved in Europe in combination with chemotherapy (carboplatin and etoposide) …
Experimental Novartis drug secures FDA Breathrough designation for rare lung cancer
September 6, 2019Medical Communications, Sales and Marketing Cancer, Novartis, capmatinib, lung cancer, pharma
Novartis is celebrating the acceptance of its experimental cancer drug capmatinib by the FDA onto an accelerated review pathway, securing …
Boehringer and Lupin team up to battle KRAS-driven cancers in $700m+ deal
September 5, 2019Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, KRAS, Lupin, collaboration, pharma
Boehringer Ingelheim is set to join forces with Lupin after the pair sealed a partnership agreement to develop, license, and …
Cancer drugs have surged since the 80s to account for 1 in 4 FDA approvals, report reveals
September 5, 2019Research and Development, Sales and Marketing Cancer, FDA, US, pharma
The number of cancer drug approvals in the US has surged over the last decade to account for over one …
Mylan gets provisional FDA greenlight for generic version of Lilly’s blockbuster cancer drug Alimta
September 2, 2019Sales and Marketing Alimta, Cancer, Eli Lilly, FDA, Mylan, pharma
Mylan has scored a preliminary approval in the US from the FDA for its generic version of Eli Lilly’s blockbuster …
Latest content
Five Facts about cardiovascular disease
